Specialist pharmaceutical company Open Orphan said its subsidiary Venn Life Sciences has agreed a contract renewal deal with a major global pharmaceutical client worth £1.5m over two years.
The renewed contract will start in January 2022.
The Venn team, based in Breda in the Netherlands, will provide dedicated clinical pharmacokinetics support to the company on several drug development programmes, to study the absorption, distribution, metabolism and excretion of drugs within the body.
Venn, which has been a part of Open Orphan since 2019, offers a combination of drug development consultancy, clinical trial design and execution.
These combined services enable Venn to provide its clients with a complete end-to-end service on all the stages of their drug development programmes, from the early planning phase to final execution.
Cathal Friel, executive chairman of Open Orphan, said the company was delighted to see this contract renewal signed by the Venn team in Breda with a client that it has been working with since 2012.
"The continued support by Venn to a distinguished partner such as this demonstrates the value of Venn's clinical pharmacokinetics offering, as part of its comprehensive offering in drug development consultancy, clinical trial design and execution," Mr Friel said.
"Open Orphan's strengths lie in the established relationships we have with our pharmaceutical partners and we expect to continue to develop these relationships as well as focusing on converting our existing pipeline of new business opportunities," he added.
